Protagonist Therapeutics

$23.85
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.72 (+3.11%) Today
$0.00 (0.00%) As of 1:07 PM EST after-hours

Why Robinhood?

You can buy or sell PTGX and other stocks, options, and ETFs commission-free!

About PTGX

Protagonist Therapeutics, Inc. engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. Its product pipeline include PTG-300, PTG-200, and PN-943 The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA. The listed name for PTGX is Protagonist Therapeutics, Inc. Common Stock.

CEO
Dinesh V. Patel
Employees
73
Headquarters
Newark, California
Founded
2006
Market Cap
912.42M
Price-Earnings Ratio
Dividend Yield
Average Volume
438.05K
High Today
$24.96
Low Today
$23.23
Open Price
$23.49
Volume
218.45K
52 Week High
$24.96
52 Week Low
$4.47

Collections

PTGX Earnings

-$1.18
-$0.79
-$0.39
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 9, After Hours

You May Also Like